Scienture reports preliminary Q3 2026 revenue of $1.22 million, up sharply on Rezenopy launch
The company's second FDA-approved product, Rezenopy nasal spray, began commercial shipments in August 2026, lifting preliminary quarterly revenue alongside continued Arbli growth.
Scienture Holdings, Inc. (NASDAQ: SCNX) said on October 13, 2026 that it expects preliminary, unaudited revenue of approximately $1.22 million for the third quarter ended September 30, 2026, representing an increase of 256% compared to approximately $344,000 in the second quarter of 2026.1 The company attributed the jump to the commercial launch of REZENOPY and initial wholesale shipments, along with ongoing sales growth and expanding market uptake of Arbli1. Scienture called the quarter a milestone marking the addition of a second FDA-approved product and progress toward a multi-product portfolio1.
On the Arbli side, the company reported that wholesale unit sales increased 74% sequentially, with recent institutional formulary additions supporting continued commercial expansion1.
REZENOPY (naloxone hydrochloride) Nasal Spray 10mg is described in the release as an opioid antagonist indicated for emergency treatment of known or suspected opioid overdose, manifested by respiratory and/or central nervous system depression, in adult and pediatric patients1, and is intended for immediate administration as emergency therapy in settings where opioids may be present1.
Separately, in a Nasdaq listing update included in the same filing, Scienture said it had previously been notified on October 14, 2025 that it was out of compliance with the exchange's minimum bid price rule, and was later given an additional 180-day compliance period, running until October 12, 2026, to regain compliance1. The company stated that on October 19, 2026 it received written notice that its closing bid price had been at least $1.00 per share for ten consecutive trading days between October 5 and October 16, 2026, and that it had regained compliance with the Minimum Bid Price Requirement.1 Nasdaq determined the matter is now closed and the company's securities will remain listed for trading on Nasdaq.1
The filing notes that the preliminary revenue figures are unaudited and subject to customary adjustments, with full Q3 2026 results to be included in a Form 10-Q filed with the SEC.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.